A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

A capsule socket of a filling machine for two-piece capsules and a socket system having such a capsule socket and a capsule half of a two-piece capsule are disclosed herein. The two-piece capsules have two capsule halves, each with a capsule base and a capsule wall. The capsule socket includes a main body having a receiving space for the capsule half formed therein. The receiving space has a base portion, assigned to the respective capsule base, and a circumferential wall portion for centering the capsule wall. The receiving space has a clamping portion between the base portion and the circumferential wall portion. The clamping portion has a smaller free cross section than the circumferential wall portion. In the transition region from its base to its wall, the capsule half has a capsule part diameter. The clamping portion has a free clamping diameter, which is smaller than the capsule part diameter.

Provided are enrobed gastric residence dosage forms comprising: a gastric residence system in a folded configuration; and a coating enrobing the gastric residence system in the folded configuration, wherein the enrobed gastric residence dosage form is configured to release the gastric residence system in the folded configuration in a stomach of a patient, allowing the gastric residence system to assume an open configuration. The coating comprises water, a plasticizer, a gelling agent, and/or a polymer.

Provided are gastric residence dosage forms comprising: a gastric residence system in a folded configuration; a capsule encapsulating the gastric residence system in a folded configuration; and a coating on the capsule, wherein the gastric residence dosage form is configured to release the gastric residence system in a stomach of a patient, allowing the gastric residence system to assume an open configuration. The coating on the capsule includes a polymer, an anti-tacking agent, and/or a hydration aid.

A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multi phase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.

A multi phase soft gelatin dosage form comprising at least one preformed solid dosage form and at least one liquid fill phase. The multi phase soft gelatin dosage forms of the present invention are especially useful to combine at least one solid dosage form and at least one liquid phase for single ingestion. Method and apparatus for manufacturing the multi phase soft gelatin dosage forms are also described. The solid phase, liquid phase or coatings may comprise active pharmaceutical ingredients, nutraceuticals, nutritional supplements, therapeutic substances, functional excipients or combinations thereof.

This disclosure generally relates to systems and methods for detecting, monitoring, and responding to abnormalities in an infant's breathing. One or more sensing devices may collect infant breathing related data, which may be filtered and converted to a frequency signal. The frequency signal may be monitored for irregularity or stoppage, and a processing module may determine whether the irregularity or stoppage is caused by an actual stoppage or irregularity in infant breathing. If infant breathing is determined to have stopped, a corrective action may be performed.

The membrane dosing system for controlled release of substances from the container provides controlled release characteristics (delayed, prolonged and intensity) of one or more active substances from one or more different parts of the same container housed in a medium that dissolves (erodes) membranes into an environment. The dosage system shown consists of three basic parts, two outer elements (2 and 4) and one internal dividing element (3) which is connecting the outer elements (2 and 4) and forming two compartments (5 and 6). The membranes (7 and 8) can be of different shapes and thicknesses. Compartments (5 and 6) are spaces for inserting a substance that may be same or different. The thickness, diameter and shape of the membranes (7 and 8) determine the moment at which the contents will start to leak from of one individual compartment of the (capsule) container into the environment.

A pharmaceutical product including a housing that defines a cavity, wherein the cavity stores a pharmaceutical material, and wherein the housing comprises a material configured to dissolve based on contact with a fluid, an ingestible device to encode information in a current signature, wherein the ingestible device is positioned within the housing, and a protective material that encompasses the ingestible device. The ingestible device may be attached to a flexible component, wherein the flexible component is configured to releasably secure the ingestible device within the housing.

This disclosure generally relates to systems and methods for detecting, monitoring, and responding to abnormalities in an infant's breathing. One or more sensing devices may collect infant breathing related data, which may be filtered and converted to a frequency signal. The frequency signal may be monitored for irregularity or stoppage, and a processing module may determine whether the irregularity or stoppage is caused by an actual stoppage or irregularity in infant breathing. If infant breathing is determined to have stopped, a corrective action may be performed.